Testing and Monitoring Mesothelioma: The Mesomark Assay

The Mesomark Assay works as an in vitro test to monitor and potentially diagnose mesothelioma. Developed by Fujirebio Diagnostics and approved in late January 2007 by the FDA, it works by measuring levels of soluble mesothelin-related proteins (SMRPs) released by diseased mesothelioma cells. The SMRP levels correlate directly with tumor volume thus permitting less invasive monitoring and improved assessment of treatment response. In the future, the test may be used as an early detection measure as evidenced by recently sponsored tests by the Early Detection Research Network of the National Cancer Institute.

Weitz & Luxenberg is a leading plaintiffs' law firm that has represented people affected by mesothelioma for over 20 years. Men and women diagnosed with mesothelioma caused by asbestos exposure may be entitled to compensation from the companies responsible for their disease.

If you would like a free consultation or more information about your legal options, please complete the form below, and a representative of our law firm will contact you as soon as possible.